Technology
Health
Biotechnology

Vaxart

$2.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-11.11%) Today
+$0.04 (1.92%) After Hours

Why Robinhood?

You can buy or sell Vaxart and other stocks, options, ETFs, and crypto commission-free!

About

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. Read More The company was founded in 2004 and is headquartered in South San Francisco, CA.

Employees
34
Headquarters
South San Francisco, California
Founded
2004
Market Cap
16.71M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
282.95K
High Today
$2.27
Low Today
$2.01
Open Price
$2.14
Volume
573.52K
52 Week High
$7.60
52 Week Low
$1.44

Collections

Technology
Health
Biotechnology
Medical
US
North America

News

Seeking Alpha4h

Vaxart closes $3M capital raise

Vaxart (NASDAQ:VXRT) has closed its direct offering of 1.2M common shares at $2.50 per share yielding gross proceeds of $3M....

47
Yahoo FinanceMar 19

Watch These Four Healthcare Stocks Set The Pace On Tuesday

CORAL GABLES, FL/ ACCESSWIRE / March 19, 2019 / In the last few months, the healthcare stock market has responded favorably to the fact that the healthcare industry is one of the fastest changing sectors in the global marketplace.

1,461
Associated PressMar 19

Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 19, 2019--Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b bivalent norovirus vaccine clinical trial. β€œThe initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step towards our goal of developing a vaccine that can protect the most vulnerable patients from this highly infectious disease,” ...

120

Earnings

-$1.24
-$1.06
-$0.87
-$0.69
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected May 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.